Evidence map›Paper›PMID 34227708›Full record

Trial reportAlimentary pharmacology & therapeutics2021

Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease.

Seung Han Kim, Kwang Bum Cho, Hoon Jai Chun, Sang Woo Lee, Joong Goo Kwon, Dong Ho Lee, Sang Gyun Kim, Hwoon-Yong Jung, Ji Won Kim, Joon Seong Lee and 13 more

2 registry-linked trialsAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Alimentary pharmacology & therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 43 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02556021 phase3completednot on this map

A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of CJ-12420 in Patients With Non-erosive Reflux Disease

TypeinterventionalSponsorHK inno.N CorporationRan2015 to 2016Enrolled324ConditionsNon-erosive Reflux DiseaseArmsCJ-12420 50mg, CJ-12420 100mg, Placebo
NCT07687706 phase3recruitingnot on this mapstarted 2026, after this paper: background citation

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Superiority, Investigator-initiated Trial of Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke)

TypeinterventionalSponsorHanyang University Guri HospitalRan2026 to 2027Enrolled1,524ConditionsIschemic Stroke, Ischemic Stroke, Acute, Transient Ischemic Attack (TIA), Cerebrovascular DiseaseArmsTegoprazan 50 mg, Placebo
3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. [Drug Therapy for Gastroesophageal Reflux Disease].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Seung Han KimSeoul, South Korea.ORCID 0000-0001-9247-9175
Kwang Bum ChoDaegu, South Korea.
Hoon Jai ChunSeoul, South Korea.ORCID 0000-0002-5539-361X
Sang Woo LeeAnsan, South Korea.
Joong Goo KwonDaegu, South Korea.
Dong Ho LeeSeongnam, South Korea.
Sang Gyun KimSeoul, South Korea.ORCID 0000-0003-1799-9028
Hwoon-Yong JungSeoul, South Korea.ORCID 0000-0003-1281-5859
Ji Won KimSeoul, South Korea.
Joon Seong LeeSeoul, South Korea.
Hyojin ParkSeoul, South Korea.
Suck Chei ChoiIksan, South Korea.
Sam Ryong JeeBusan, South Korea.
Hyun-Soo KimKwangju, South Korea.
Kwang Hyun KoSeongnam, South Korea.
Seun Ja ParkBusan, South Korea.
Yong Chan LeeSeoul, South Korea.
Soo Heon ParkSeoul, South Korea.ORCID 0000-0003-3056-8740
Ah Rong KimSeoul, South Korea.
Eun Ji KimSeoul, South Korea.
Hyun Wook ParkSeoul, South Korea.
Bong Tae KimSeoul, South Korea.
Geun Seog SongSeoul, South Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTegoprazan is a novel, fast- and long-acting potassium-competitive acid blocker that suppresses gastric acid secretion, which could benefit patients with non-erosive reflux disease (NERD), a type of gastroesophageal reflux disease.

aimTo evaluate the efficacy and safety profiles of tegoprazan compared with those of a placebo in Korean patients with NERD.

methodsIn this phase 3, double-blind, placebo-controlled, multicentre study, 324 Korean patients with NERD were randomised into three treatment groups: tegoprazan 50 mg, tegoprazan 100 mg and placebo. These drugs were provided once daily for 4 weeks. The primary endpoint was the proportion of patients with complete resolution of major symptoms (both heartburn and regurgitation) for the last 7 days of the 4-week treatment period. Other outcomes related to efficacy, safety and tolerability were also evaluated.

resultsAmong all, 42.5% (45/106), 48.5% (48/99) and 24.2% (24/99) of patients showed complete resolution of major symptoms at week 4 after receiving tegoprazan 50 mg, tegoprazan 100 mg, and placebo, respectively. Both doses of tegoprazan showed superior efficacy than the placebo (P = 0.0058 and P = 0.0004, respectively). The complete resolution rates of heartburn and proportions of heartburn-free days (as other efficacy outcomes) were significantly higher in both tegoprazan groups than in the placebo group (P < 0.05 for all). No significant difference in the incidence of treatment-emergent adverse events were noted.

conclusionsTegoprazan 50 and 100 mg showed superior therapeutic efficacy compared with the placebo, as well as a favourable safety profile in patients with NERD. Registration number: ClinicalTrials.gov identifier NCT02556021.

Indexed as

Gastroesophageal RefluxImidazolesBenzene DerivativesDouble-Blind MethodHeartburnHumansTreatment OutcomeBenzene DerivativesImidazolestegoprazan

Identifiers

PMID34227708
PMCPMC8361733

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.